Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Blood test may spot hidden cancer cells, guiding smarter treatment for esophageal cancer

NCT ID NCT07371247

Disease control Sponsor: The First Affiliated Hospital with Nanjing Medical University Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only This study
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study looks at whether a blood test that finds tiny traces of cancer DNA (called ctDNA-MRD) can help doctors decide who needs more treatment after standard chemoradiation for advanced esophageal cancer. About 65 people with unresectable cancer will get extra immunotherapy and chemo if their blood test shows leftover cancer cells. The goal is to see if this approach is safe and helps prevent the cancer from coming back.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Early phase 1

The earliest testing in people: a first look at safety, in a very small group.

Participants

About 65 people

The number the study aims to enrol. It can still change while the study runs.

Started

Dec 2025

Expected to finish

Nov 2027

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 to 80 years

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

* Inclusion Criteria 1. Histologically confirmed locally advanced esophageal squamous cell carcinoma (ESCC), with clinical stage Ⅱ-Ⅳ unresectable disease (including unresectable cases, patients with surgical contraindications, or those who refuse surgery). According to the 8th edition AJCC staging system, the pretreatment clinical stage is defined as: cT1N2-3M0, cT2-4bN0-3M0; M1 disease is limited to non-regional lymph node metastases, excluding distant organ metastases. 2. No prior systemic therapy administered for the disease, and planned to receive definitive chemoradiotherapy (dCRT). 3. Having undergone 1021-gene large panel testing on tissue samples. 4. Aged 18-80 years old. 5. Expected overall survival ≥ 6 months. 6. ECOG performance status 0-1. 7. Normal blood biochemical parameters, with normal liver and kidney function. 8. Able to understand the study protocol, voluntarily participate in the study, and sign the informed consent form. 9. Good compliance, able to cooperate with specimen collection at all designated time points and provide relevant clinical data. * Exclusion Criteria 1. Have participated in other clinical trials within 3 months prior to enrollment. 2. Have a history of other malignant tumors within 3 years prior to the diagnosis of esophageal cancer. 3. Have a history of severe mental illness. 4. Patients who are unable to understand the study protocol and thus cannot cooperate, or who refuse to sign the informed consent form. 5. Have contraindications to chemoradiotherapy. 6. Have a history of autoimmune diseases.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for CTDNA are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

bilateral multicystic dysplastic kidney esophageal cancer Esophageal Neoplasms esophageal squamous cell carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

CTDNA Esophageal cancer MRD

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    1 site. The list below names each one and where it is.

  2. The official record

    The full official record for this study. This one lists no contact details, but it is the first place any would appear.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • Jiangsu Province Hospital

    Nanjing, Jiangsu, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.